Eagan, Minnesota--(Newsfile Corp. - March 2, 2023) - Dynatronics Corporation (NASDAQ: DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that management will participate in three investor conferences in March 2023, to provide an update on the company's business.
John Krier, President and CEO of Dynatronics Corporation, will participate in the Canaccord Genuity 2023 Musculoskeletal Conference on March 7, 2023, held in Las Vegas, and will also participate in the Roth Capital Conference on March 12 - 14, 2023, held in Dana Point, California. Mr. Krier will also join the Investor Summit being held virtually on March 29, 2023. Management will be available for one-on-one meetings and will present in a group format at each of these conferences. Investors interested in scheduling one-on-one meetings are encouraged to register online, through the individual conference platforms. The presentations for the conferences can be found on the company's investor relations page at https://www.dynatronics.com/investors/.
About Dynatronics Corporation
Dynatronics Corporation is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Dynatron Solaris®, Hausmann™, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
Investor Contacts:
Dynatronics Corporation
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
For additional information, please visit: www.dynatronics.com.
Connect with Dynatronics on LinkedIn.
| Last Trade: | US$0.45 |
| Daily Change: | -0.04 -7.96 |
| Daily Volume: | 53,993 |
| Market Cap: | US$2.200M |
February 08, 2024 January 15, 2024 November 09, 2023 October 30, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
